Dr Reddy's Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dr Reddy's Laboratories (RDY).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$495Upside to Avg. PT+3715.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Citigroup	Vivek Agrawal	Upgrade	Sell→Buy	$1040→$1450
Jun 5, 2025	HSBC	Damayanti Kerai	Upgrade	Hold→Buy	$14→$17
Nov 6, 2024	Barclays	Balaji Prasad	Maintained	Overweight	$17→$17
Jul 30, 2024	Barclays	Balaji Prasad	PT Raise	Overweight	$81→$87
May 8, 2024	Barclays	Balaji Prasad	PT Raise	Overweight	$80→$81
Jan 29, 2024	Barclays	Balaji Prasad	PT Raise	Overweight	$75→$80

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

Citigroup analyst Vivek Agrawal upgrades Dr Reddy's Laboratories (NYSE:RDY) from Sell to Buy and raises the price target from $1040 to $1450.

Benzinga Newsdesk

PRO
HSBC Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $16.9

HSBC analyst Damayanti Kerai upgrades Dr Reddy's Laboratories (NYSE:RDY) from Hold to Buy and raises the price target from $14.44 to $16.9.

Benzinga Newsdesk

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Vandana Singh

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $81 to $87.

Benzinga Newsdesk

Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug

Dr.

Zacks

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $80 to $81.

Benzinga Newsdesk

Dr Reddy's Laboratories Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Dr Reddy's Laboratories Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

PRO
HSBC Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $16.9

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81

People Also Watch

People Also Watch

Dr Reddy's Laboratories Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Dr Reddy's Laboratories Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

PROHSBC Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $16.9

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

PROBarclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug

PROBarclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81

People Also Watch

People Also Watch

PRO
Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

PRO
HSBC Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $16.9

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81